GLPwatch
Papers (10389)
Page 166 of 174, ranked by citation count.
- Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.
- Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes.
- Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.
- Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050.
- Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis.
- Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.
- Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes".
- Familial partial lipodystrophy type 2 associated with a novel LMNA variant (c.604G>C; p.Glu202Gln): a Colombian family case series.
- [In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.]
- Lixisenatide in the treatment of Type 2 diabetes.
- Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.
- The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions.
- From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.
- The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: <i>A Multicenter Saudi Arabian Study</i>.
- Exenatide administration time determines the effects on blood pressure dipping in <i>db/db</i> mice via modulation of food intake and sympathetic activity.
- Real-world healthcare resource utilization and medical costs in patients with overweight or obesity and multimorbidity treated with semaglutide in the United States.
- Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion.
- Association between incretin-related drugs and fractures in patients treated with pioglitazone: A pharmacovigilance study using the FDA Adverse Event Reporting System.
- Serial assessment of NT-proBNP and high-sensitivity cardiac troponin with glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes: Insights from EXSCEL.
- Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.
- Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
- Discovery of Small-Molecule GLP‑1 Receptor Agonists with Improved Oral Pharmacokinetics Based on Orforglipron.
- Exendin-4 - A potential therapeutic for type 2 diabetes-linked cervical cancer?
- Expanded table: some available insulins for type 2 diabetes.
- Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.
- Lixisenatide for type 2 diabetes.
- Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
- [Weight reduction with incretin mimetics-Opportunities and risks].
- Development of Cardiovascular Risk Equations in People with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes Based on the SELECT Trial.
- [Type 2 diabetes. Lixisenatide - effective in combination].
- [The weight-loss injection : An orthopaedic overview].
- Tirzepatide improves neutrophilic inflammation in obese asthmatic mice by downregulating Th17 cell differentiation.
- Diabetes News.
- A Single-dose, Two-Period Crossover Bioequivalence Study Comparing Two Liraglutide Formulations in Healthy Chinese Subjects.
- Efficacy and Safety of Dulaglutide for Weight Reduction Among Diabetic Patients in Saudi Arabia: A Retrospective Cohort Study.
- [Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].
- No evidence that tirzepatide can worsen diabetic retinopathy. Reply to Fadini GP [letter]. Reassessing retinopathy risk with tirzepatide therapy. Reply to Zhang N, Wang W, Wan G [letter].
- Dual GIP/GLP-1 receptor agonist tirzepatide ameliorates hepatic steatosis and inflammatory responses in a MASLD mouse model associated with the CCL2/CCR2 axis.
- Tirzepatide and the Cardiovascular Continuum: Metabolic, Cardiorenal and Heart Failure Evidence.
- An Online Prescription for Hospitalisation: Euglycaemic Ketoacidosis Caused by an Online Tirzepatide Prescription.
- Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study.
- Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation.
- Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.
- RFX6 maturity-onset diabetes of the young: clinical considerations and novel use of tirzepatide.
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.
- Complete Skin Remission of Lichen Planus With Tirzepatide.
- Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.
- Tirzepatide-associated hyponatremia in a patient with known arginine vasopressin deficiency.
- Evaluating Semaglutide's Protection in H/R - Injured AC16 Cardiomyocytes: Oxidative Stress, Inflammation, Apoptosis, and Autophagy Insights.
- Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide.
- Bispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.
- Cost-Minimisation Analysis of Dapagliflozin Compared To Lixisenatide As An Add-On To Insulin In The Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective.
- Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea.
- Neuroprotective effects of semaglutide targeting the left temporal lobe in adults with overweight or obesity: A 24-week multimodal neuroimaging study.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.
- Summary for Patients: Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide.
- Dulaglutide efficacy.
- REWIND Diabetes for Octogenarians.
- Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF.
- Any expectations from the more powerful dulaglutide?